Immunology of inflammatory bowel disease and molecular targets for biologics

Maneesh Dave; Konstantinos A Papadakis; William A Faubion Jr

doi:10.1016/j.gtc.2014.05.003

Immunology of inflammatory bowel disease and molecular targets for biologics

Gastroenterol Clin North Am. 2014 Sep;43(3):405-24. doi: 10.1016/j.gtc.2014.05.003.

Authors

Maneesh Dave¹, Konstantinos A Papadakis¹, William A Faubion Jr²

Affiliations

¹ Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
² Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: faubion.william@mayo.edu.

Abstract

Inflammatory bowel disease (IBD) is an immune-mediated disease and involves a complex interplay of host genetics and environmental influences. Recent advances in the field, including data from genome-wide association studies and microbiome analysis, have started to unravel the complex interaction between host genetics and environmental influences in the pathogenesis of IBD. A drawback of current clinical trials is inadequate or lack of immune phenotyping of patients. However, recent advances in high-throughput technologies provide an opportunity to monitor the dynamic and complex immune system, which may to lead to a more personalized treatment approach in IBD.

Keywords: Adaptive immunity; Biologics; IBD; Immunology; Innate immunity.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Dendritic Cells / immunology
Humans
Immunity, Innate*
Immunity, Mucosal*
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / immunology*
Intestines / microbiology*
Macrophages / immunology
Microbiota
T-Lymphocytes / immunology*

Grants and funding

R01 AI089714/AI/NIAID NIH HHS/United States